Brazil Alzheimer’s Therapeutics Market Analysis

Brazil Alzheimer’s Therapeutics Market Executive Summary

Brazil Alzheimer’s Therapeutics Market was valued at $120 Mn in 2022 and is estimated to reach $259 Mn in 2030, exhibiting a CAGR of 10.1% during the forecast period.

Alzheimer's is a neurological disorder that affects mental, behavioural, and memory abilities. Usually, it begins gradually, worsens over time, and makes it more difficult for the person to carry out everyday duties. In Alzheimer's disease, aberrant brain changes like plaque and tangle accumulation cause nerve cells to die. There is presently no treatment for Alzheimer's disease. Conversely, some medications can improve quality of life and help control symptoms. These drugs, which include memantine, rivastigmine, and donepezil, regulate certain neurotransmitters in the brain to treat memory and cognitive problems. In addition, there are non-pharmacological methods such as upholding a healthy lifestyle, participating in social and cognitive activities, and creating a supportive atmosphere that can enhance the overall management of sickness.

The incidence of dementia is 6.1% in Brazil, with significant age-group differences: 3.3% for people 60–64 years old and 43.0% for people 90 years of age and older. The prevalence of Alzheimer's disease is 313 cases per 100,000 people. While the prevalence rates show negative correlations with ultra-processed food consumption and physical activity levels, they also show favourable correlations with primary health care coverage-related characteristics. 98 cases of Alzheimer's disease occur for every 100,000 people. The death rate from the disease is positively correlated with the percentage of older people who are obese and who make up to half of the minimum wage, but it is inversely correlated with the percentage of older people who have diabetes-related factors.

Brazilian research facilities are actively involved in international clinical trials aimed at developing treatments for Alzheimer's disease. These studies involve the investigation of novel compounds that address different aspects of the disease, such as tau-targeting antibodies and BACE inhibitors.

Associação Brasileira de Alzheimer (ABRAZ) and Movimento Viva Bem com Alzheimer, are important Brazilian organizations that advocate for the early detection of Alzheimer's disease and raise awareness of the condition. The exchange of knowledge is facilitated by the joint efforts of pharmaceutical corporations, healthcare professionals, and patient advocacy groups, which eventually improves the quality of care rendered.

Market Dynamics

Market Growth Drivers

Increasing Aging Population: Brazil's population is aging faster than that of many other nations as a result of a demographic change. The demand for efficient treatment alternatives is expected to increase as the number of seniors increases and the prevalence of Alzheimer's disease rises.

Government Initiatives and Policies: Supportive policies and initiatives from the Brazilian government, like the National Alzheimer's Plan, are actively investing in research, diagnosis, and treatment of Alzheimer's disease. Government backing for research, healthcare infrastructure, and accessible treatment options can foster market growth.

Increased Awareness and Early Diagnosis: More people are seeking therapy for Alzheimer's because of increased public knowledge through proactive initiatives by organizations such as Associação Brasileira de Alzheimer (ABRAZ) and Movimento Viva Bem com Alzheimer of the illness and advancements in testing technology, which facilitate early diagnosis. The window of opportunity for potential improvement is extended when actions involving prospective disease-modifying medications are started early.

Market Restraints

Lack of Awareness and Stigma: Despite the growing number of awareness programs, many people are prevented from receiving a diagnosis and treatment for dementia and Alzheimer's disease due to the persistent societal stigma associated with these conditions. One significant barrier preventing the market from reaching a wider clientele is this stigma.

High Drug Costs and Affordability Concerns: The exorbitant expense of Alzheimer's therapy poses a significant obstacle to access for many sufferers. Given the current state of the insurance industry's coverage of certain pharmaceuticals, this issue is critical. Even with insurance, co-payments can put a heavy financial burden on patients and their families.

Limited Efficacy and Uncertain Long-Term Benefits: There are doubts about the long-term viability and efficacy of current medications, such as Leqembi and Aduhelm, in slowing down cognitive decline. Various factors contribute to hesitancy, such as the absence of a definitive treatment or conclusive evidence of better health.

Healthcare Policies and Regulatory Landscape

Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian Health Regulatory Agency, is in charge of overseeing treatment drug regulations and healthcare laws. Pharmaceutical companies need to submit extensive safety, effectiveness, and quality data for ANVISA approval in order to bring therapeutic medications, including Alzheimer's treatments, to market. ANVISA is in charge of managing the complete medication lifecycle, which includes pharmacovigilance efforts to guarantee continued safety, post-marketing surveillance, and analysis of clinical trial outcomes. Sistema Único de Saúde (SUS), the public healthcare system run by the Brazilian government, sets reimbursement guidelines that affect the availability and cost of treatment medications. The rights of pharmaceutical businesses are also protected by intellectual property regulations.

Competitive Landscape

Key Players

• Pfizer
• Biogen
• Janssen
• Eisai
• Novartis
• Roche
• Lundbeck
• Otsuka Pharmaceutical
• Teva Pharmaceutical
• Sun Pharmaceutical